Specialty Laboratories Inc.Symbol: SP Exchange: NYSE NYSE See: New York Stock Exchange Close: 10.00 1-WK % Chg: -5.5% Business Overview Specialty Laboratories Inc. is a hospital-focused clinical laboratory performing highly advanced, clinically useful testing services for hospitals, laboratories and physician-specialist communities in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The company offers a comprehensive menu of esoteric assays, consisting of more than 2,500 assays. Esoteric assays are complex, comprehensive or unique tests used to diagnose, evaluate and monitor patients. The company's primary customers are hospitals, independent clinical laboratories and physicians, The company has historically leveraged its expertise in molecular diagnostics and applied it to high-growth segments of the esoteric testing esoteric test Lab medicine The analysis of 'rare' substances or molecules that are not performed in a routine clinical lab. See DORA. industry, including fields of medicine such as infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , gastroenterology gastroenterology Medical specialty dealing with digestion and the digestive system. In the 17th century Jan Baptista van Helmont conducted the first scientific studies in the field; William Beaumont published his own observations in 1833. , oncology, endocrinology and cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. . Molecular diagnostic assays comprised approximately 32% of the company's net revenue for 2002. Molecular diagnostics includes all test procedures incorporating or identifying DNA- or RNA-based targets. Income Statement LTM '03 * 2002 ** Revenue (in millions) $126.9 $140.2 Operating Income (in millions) (20.8) (15.5) Net Income (in millions) (16.1) (13.4) EPS ($0.74) ($0.61) Summary Headquarters: Santa Monica Market Cap: $221.2 million Dividend Yield: NA *** P/E Ratio: NA * Latest twelve months ended Mar. 31, 2003 ** Fiscal year ended Dec. 31, 2002 *** Company does not pay dividends. SPECIALTY LABORATORIES INC. Aug. 6, 2002 $7.20 Aug. 6, 2003 $10.00 [GRAPHIC OMITTED] |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion